Symmetry Medical Upgraded by Northcoast Research to Buy (SMA)
Symmetry Medical (NYSE:SMA) was upgraded by research analysts at Northcoast Research from a “neutral” rating to a “buy” rating in a report released on Tuesday, TheFlyOnTheWall.com reports.
Symmetry Medical (NYSE:SMA) remained flat at $9.61 during during mid-day trading trading on Tuesday. The stock had a trading volume of 616,887 shares. Symmetry Medical has a 52 week low of $7.69 and a 52 week high of $11.11. The stock has a 50-day moving average of $8.97 and a 200-day moving average of $9.23. The company’s market cap is $360.3 million.
Symmetry Medical (NYSE:SMA) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.12 by $0.05. The company had revenue of $101.30 million for the quarter, compared to the consensus estimate of $98.38 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts predict that Symmetry Medical will post $0.54 earnings per share for the current fiscal year.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of Symmetry Medical in a research note on Friday, June 20th. They now have a $9.25 price target on the stock.
Symmetry Medical Inc (NYSE:SMA) is a medical device solutions company, including surgical instruments, orthopedic implants, and sterilization cases and trays.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.